Business Wire

Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Launch of First Motion Capture Facility Outside United States

8.9.2021 15:29:00 EEST | Business Wire | Press release

Share

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) is pioneering a first-in-the-region Motion Capture (MOCAP) facility. Outside of the United States, SSRC’s unique MOCAP facility at its Masdar City premises, will enable the testing of Unmanned Aerial Systems (UAS) or drones in an augmented reality (AR) or mixed reality environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005700/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr Shreekant (Ticky) Thakkar, Chief Researcher, Secure Systems Research Centre, Technology Innovation Institute (Photo: AETOSWire)

The MOCAP facility will allow SSRC to simulate flying through the city of Abu Dhabi and enable high-precision ground truth to conduct sophisticated experiments as well as virtual, augmented and mixed reality testing. The ability to simulate virtual camera images and sensors facilitates testing in environments that are too large, too dangerous, or too time consuming to construct in reality.

The high-quality motion capture system proposed for Abu Dhabi will be able to conduct passive or active tracking and enhance the communication, navigation, command, and control capabilities achieved to date. SSRC is shaping this facility in line with its ongoing collaboration with US-based Purdue University that holds the distinction for the largest indoor motion capture facility in the world.

Speaking on the breakthrough facility that will allow the modelling and operation of a cloud-based secure autonomous system of drones - as opposed to just autonomous drones - in this environment, Dr Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “This is a start – an ambitious one – and we are confident we will be able to arrive at technologies that could limit malicious cyber-attacks as our reliance on drones continues to increase every day. They are integral to life today – from delivering valuable organs at a hospital to conducting surveillance of high-security zones, or dispersing seeds over a field or even completing grocery deliveries.

“This unique testing facility will be leveraged by various lab groups and allow us to conduct experiments on a broad range of Unmanned Aerial Systems of various sizes while the state-of-the-art high-resolution cameras track small objects in the surrounding environment. Our aim at SSRC is to develop breakthrough security solutions to safeguard systems that may be vulnerable, such as unsecure drone systems which may pose various threats to organisational or even individual privacy and safety. Therefore, it’s essential to make drone platforms more resilient and secure.”

On the construction of the new facility, James Goppert, Managing Director of the Purdue UAS Research and Test Facility said: “Autonomous drones are already playing a key part in package delivery and infrastructure inspection. As smart cities evolve, it will be critical to ensure the safe operation of drones in an urban setting. This facility is particularly suited to the task of bringing algorithms for the security of drones from simulation to real world application by allowing a gradual transition of scenario elements from pure simulation, to virtual, to real-world.”

The testing facility will be used by both the Secure Systems Research Centre and TII’s Autonomous Robotics Research Centre to carry out experiments on a range of vehicles. As a shared space, the Motion Capture facility can accommodate micro UAS weighing less than 10 g to large UAS that are as heavy as 1,000 kg and factor in different types of UAS from multirotor to helicopters to vertical takeoff and landing vehicles (VTOLs) to fixed wing craft.

For information on Technology Innovation Institute, visit www.tii.ae

For information on Secure Systems Research Centre, visit https://securesystems.tii.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release

Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl

IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release

IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w

Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release

SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye